What this means
This trial plans to test whether a calcium and vitamin D supplement helps people keep muscle while starting semaglutide. It has not started recruiting, so no results exist yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 65–85
- Where
- 1 site, including Tennessee
The science
- Registered title
- HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide
- Trial ID
- NCT07760948 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults
- What is tested
- Calcium-HMB Plus Vitamin D3, Matching placebo
- Sponsor
- Vanderbilt University Medical Center
- Ages
- 65 Years to 85 Years
- Dates
- First posted Aug 12, 2026 · updated Aug 28, 2026
Registry summary
This randomized, double-blind, placebo-controlled trial will evaluate whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care. Participants will receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6. Secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, resting metabolic rate, metabolic measures, and whole-body quantitative computed tomography. An optional mechanistic substudy of up to 36 participants will include D3-creatine dilution, nonradioactive stable isotope infusions, repeated blood sampling, a standardized meal, breath sampling, and vastus lateralis muscle biopsies at baseline and month 6.
Sites (1)
- Vanderbilt University Medical Center, Nashville, Tennessee, United States